Vorinostat in solid and hematologic malignancies (2009)
Siegel, David, Hussein, Mohamad, Belani, Chandra, Robert, Francisco, Galanis, Evanthia, Richon, Victoria M, ...
Abstract Vorinostat (Zolinza ® ), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with...
Welcome To International Seminars In Surgical Oncology (2004)
Singh-Ranger, Gurpreet, Hussein, Mohamad
Abstract This editorial marks the launch of a new online journal for surgical and medical oncology. The internet has produced a profound shift in the way in which clinicians, researchers and patients...
He, Xing-Yue, Elson, Paul, Pohlman, Brad, Lichtin, Alan, Hussein, Mohamad, Andresen, Steve, ...
Abstract Background The timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia...
Welcome To International Seminars In Surgical Oncology
Singh-Ranger, Gurpreet, Hussein, Mohamad
This editorial marks the launch of a new online journal for surgical and medical oncology. The internet has produced a profound shift in the way in which clinicians, researchers and patients seek,...
Chen, Quan, Gong, Bendi, Mahmoud-Ahmed, Ashraf S., Zhou, Aimin, Hsi, Eric D., Hussein, Mohamad, ...
It has been reported that interferons (IFNs) may have antitumor activity in multiple myeloma (MM). The mechanism for their effect on MM, however, remains elusive. This study shows that IFN-α and...
Welcome To International Seminars In Surgical Oncology
Singh-Ranger, Gurpreet, Hussein, Mohamad
This editorial marks the launch of a new online journal for surgical and medical oncology. The internet has produced a profound shift in the way in which clinicians, researchers and patients seek,...
Vorinostat in solid and hematologic malignancies
Siegel, David, Hussein, Mohamad, Belani, Chandra, Robert, Francisco, Galanis, Evanthia, Richon, Victoria M, ...
Vorinostat (Zolinza®), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous...
Proteomic Contributions to Personalized Cancer Care*
Koomen, John M., Haura, Eric B., Bepler, Gerold, Sutphen, Rebecca, Remily-Wood, Elizabeth R., Benson, Kaaron, ...
Cancer impacts each patient and family differently. Our current understanding of the disease is primarily limited to clinical hallmarks of cancer, but many specific molecular mechanisms remain...